Jasper Closes Kira Merger, Raises $132M PIPE, and Licenses C5a Programs to Mirador
JSPR has more than doubled off its 52-week low of $0.315 on elevated volume (21× avg).
Summary
Jasper Therapeutics completed its all-stock acquisition of Kira Pharmaceuticals, shifting majority ownership to former Kira holders. The deal closed alongside a $132 million PIPE of non-voting preferred stock, strengthening a balance sheet that had dwindled to $14.1 million in cash and faced a going concern warning. Separately, Kira licensed its anti-C5a and C5aR programs to Mirador Therapeutics for $12 million upfront and up to $458.5 million in milestones plus royalties, monetizing non-core assets. The merger and financing address the immediate cash crisis and Nasdaq delisting risk, while the Mirador deal adds near-term cash. A CVR tied to a potential $30 million priority review voucher for briquilimab provides additional upside for legacy holders.
At the time of this announcement, JSPR was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.7M. The 52-week trading range was $0.32 to $3.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.